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EDUCATIONAL OBJECTIVES 
In this chapter the reader will learn: 
1. the development of liver transplantation in its historical context. 
2. the developmental methods for immunosuppression leading to 
cyclosporine and cyclosporine-steroid therapy. 
3. the principles of titration of IV and then oral administration of 
cyclosporine therapy to whole blood concentrations of 800-1000 ng/ 
ml measured by immunoassay. 
4. the technical application of veno-venous bypasses and other technic-
al surgical problems during total hepatectomy in adult and pediat-
ric recipients. 
5. the problems and outcome for retransplantation. 
6. the principles of harvesting the liver from hemodynamically unsta-
ble donors. 
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HISTORICAL BACKGROUND 
The pathetic and often hopeless state of victims of end-stage liver dis-
ease has been well known to critical care physicians since the beginning 
of their specialty. All too little could be done. Because of the multiplicity 
of hepatic functions that can become deranged simultaneously, the symp-
tomatic treatment of such patients in intensive care units has been an ex-
ercise in multiple brush-fire control. 
From an economic point of view, the magnitude of the problem can be 
appreciated from the study of O'Donnell et al (1). Five years ago, when the 
dollar was worth more than today, they cost accounted the treatment of 
adult patients with end-stage hepatic disease who had a single bout of 
gastrointestinal bleeding. The bills were more than $35,000 ifno surgical 
procedure was involved, and more than $50,000 if any kind of surgical 
intervention was carried out. Since hemorrhages and other complications 
of chronic liver failure tend to occur repeatedly, the cost of dying can be 
astronomical. 
It is quite remarkable to reflect on the change in attitudes of critical 
care physicians about victims ofliver disease that has occurred in the last 
5 years; instead of being a nuisance, the mortally ill "liver patient" has 
become a challenge. It was during these 5 years that the value of liver 
transplantation became obvious first to those who were evolving the 
methodology,. and then to others. Most of the developments have taken 
place at the University of Pittsburgh, where the liver surgery team com-
bined its efforts with the remarkable intensive care program headed by 
Ake Grenvik. Grenvik and his assistants at the Presbyterian-University 
Hospital, including James Snyder and the pediatric intensivists Richard 
Orr, Ann Thompson and Richard Schieber have been pivotal figures in 
making liver transplantation practical. . 
Experimental Studies 
My own experience with liver replacement began in the summer of 
1958 when I came to Northwestern University in Chicago from the Uni-
versity of Miami. I had developed a technique for total hepatectomy in 
dogs which became a widely used method in experimental laboratories 
(2). While using this preparation in the performance of metabolic studies, 
it was obvious how simple (at least conceptually) it would be to put a new 
liver back in the evacuated hepatic fossa. Veno-venous bypass techniques 
were developed which made the experimental hepatectomy practical for 
the first canine liver replacement experiments (3). 
About 2 or 3 weeks before we performed our first orthotopic liver 
transplantation in dogs, Moore and his associates (4) using quite different 
techniques, had undertaken a similar study of liver replacement at the 
Peter Bent Brigham Hospital in Boston. At first, both our efforts in 
Chicago and those in Boston failed. At Northwestern University 79 ortho-
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topic liver transplantations produced only 19 recipients that survived for 
as long as 4 days. However, by the end of this experience, the operation 
had become almost routine. Eight of the last 11 animals survived the op-
eration and, although they were not given immunosuppressive therapy, 
one of the dogs lived for 20112 days (3,5). Initial efforts at immunosup-
pression using total-body irradiation were completely unsuccessful (6). It 
was more than 2 years before long-term survival of canine liver recipients 
became common, using azathioprine (7,8). Subsequently, the same thing 
was accomplished using anti-lymphocyte serum (ALS) or its globulin de-
rivative, ALG (9). A further encouraging fact was that it was possible in 
many animals to discontinue immunosuppressive treatment at a surpris-
ingly early time with very prolonged subsequent survival (7,9,10). These 
observations suggested that the liver had a biologic advantage in its re-
sistance to rejection, even though it was the most difficult organ to 
tranplant technically. 
CLINICAL TRIALS, 
The Pre-Cyclosporine Era 
The first attempt at liver transplantation in March 1963 failed with 
the death ofthe patient on the operating table (11). Four more attempts 
that year also were unsuccessful, although survival of more than 3 weeks 
was obtained. Other failures occurred at the Peter Bent Brigham Hospi-
tal in Boston and in Paris (12). A 3-year moratorium on further efforts 
resulted. 
The first long-term survival after liver transplantation was not 
achieved until the summer of 1967 (13). The recipient was a child with a 
hepatoma. She eventually died of recurrence of her malignancy, but only 
after 400 days (10). Between then and the end of 1979, the procedure was 
so unreliable and unpredictable that its potential value could not be 
exploited. The one-year survival in the first 111 patients was barely 30%. 
In a subsequent small series of 30 patients, the one-year survival rose to 
50% but in a third series of the same size, the survival sank again (14) to 
almost the original level (Fig. 1). 
There were many reasons why the results were so unsatisfactory 
(15). Surgical errors resulted in hemorrhage, thrombosis of the graft 
blood supply, the use of poorly preserved grafts, and defects in biliary 
tract reconstruction. Furthermore, errors of judgment were made both in 
case selection and postoperative management. There was a tendency in 
those early days to attribute all postoperative hepatic dysfunction to 
homograft rejection, when in fact a significant number of patients had bil-
iary tract obstruction and others had developed hepatitis from B virus, 
cytomegalovirus, Herpes zoster and adenovirus. However, the central 
problem was that the immunosuppressive treatment available from 1963 
through 1979 was suboptimal. The margin between therapeutic and toxic 
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Fig. 1. Patient survival in the pre-cyclosporine era of the orthotopic liver transplan-
tation. Note a slight improvement in the results of a second series which could not 
be sustained in a third series that was completed just before the introduction of 
cyclosporine. Bypermission of Stanl et al (14). 
doses of azathioprine and steroids (with or without ALG) was slender at 
best and did not exist at all in many cases. Thus, it was not until a deeply 
fundamental change was made in immunosuppression that a major im-
provement was seen in the prospects for liver transplantation. This 
occurred in the last days of 1979 and early in 1980. 
The Cyclosporine Era 
The major steps in pharmacologic immunosuppression are listed in 
Table 1, beginning with the use of azathioprine as a single agent (16). All 
of the regimens were worked out with the human kidney transplantation 
model and subsequently used for the extrarenal organs (9,16-20). The 
modern era of organ transplantation began with the systematic combined 
use of azathioprine and steroids (double-drug treatment) introduced in 
Denver in 1962 and 1963 (17). The most significant further step (in 1966) 
in the next decade and a half was the addition of antilymphocyte globulin 
(ALG) as an adjunct to azathioprine and prednisone (triple-drug therapy) 
(9). 
Neither double-drug nor the triple-drug therapy allowed predictable 
results after transplantation of cadaveric organs. Thus, the introduction 
of cyclosporine by CaIne et al. (21) of Cambridge in 1979 for kidney and 
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TABLE 1 
IMMUNOSUPPRESSIVE DRUG REGIMENS AND ADJUNCTS 
DEVELOPED FOR KIDNEY TRANSPLANTATION AND APPLIED 
FOR OTHER ORGANS INCLUDING LIVER 
Year DelCribed Uoedf ... 
/IfIalu ond Reported PIloce Deficienca U ..... 
~tnloprine 1%2 (16) Boston Ineffective, dangerous No 
AUtruoprine.steroids 1963(17) Denyer Suboptimal Yes 
Thoracic duct drainage 196H18) Stocknolm Nuisance; requires 20 to )0 days pretreatment Ye, 
as adjunct 
Thymectomy as adjunct 1963 U9) Denver Unproven value No 
Splenectomy as adjunct 1963 U9) Denver No lonler necessary Ve. 
ALe as adjunct 1966 (9) Denver Suboptimal Yes 
Cyclopnospnamide 1979 U9) Denve, No advant&Jc except for patients witn Ve. 
substi.tute for uatllioprine toxicity 
az.athioprme 
Total lympMid 1979(20) , Palo Alto, Minneapolis O&ngerous; extensive preparation; not quickly No 
irradiation reversible 
Cyclosporine alone 1978-1979 (21) Cilmbridge Suboptimal Ve. 
Cyclosporine .. sterolds 1910 (22) Denver Under rYalL .. lion Ve. 
liver recipients was a major event. Although they recommended the use 
of cyclosporine alone, we quickly learned that the effective exploitation of 
this new drug required its combination with steroids (22) in the modern 
day double-drug program that almost overnight became the new stan-
dard world-wide for kidney transplantation and for the transplantation of 
all the extrarenal organs. 
With the introduction of cyclosporine, the one-year survival after 
orthotopic liver transplantation more than doubled (12) as summarized in 
Figure 2. In a group of 199 patients treated from a few months to more 
than 5 years ago, the one-year survival expectation rose from 30% to 70%. 
This improvement caused a tremendous increase in activity in other cen-
ters all over the world. 
By July 1984, there were 11 major liver centers in the United States 
and Canada, major being defined as experience with at least five trans-
plantations. The cumulative patient total in North America was 568. Al-
though only five institutions had had experience with more than a dozen 
cases (Fig. 3), the number of such "large centers" in the ensuing half year 
has grown to about 20. Other centers than those in Figure 3 have opened. 
In Europe, nine groups with more than five cases were active as of July 
1984 (Fig. 4), and in another seven cities, smaller programs had started. 
The total European recipients was 424. Both in the United States and in 
Europe, a network ofliver exchange and sharing of patients had already 
become a practical possibility. 
Further Notations on Survival 
As already noted, nearly one thousand patients were treated with liv-
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Fig. 2. Life survival curves of patients treated by us with conventional 
immunosuppression before 1980 (lower curve), versus those treated with 
cyclosporine and steroids in 1980-1984. 
er tranplanation by July 1, 1984. That number probably doubled in the 
ensuing 6 months. It has been impossible to keep up with survival statis-
tics from all these groups. Consequently, I will concentrate on survival in 
our own senes. 
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Fig. 3. Liver tranpiantation centers in the United States in Juiy, 1984. Teams with 
five or more cases are designated with large dots. By permission ofStarzl et ai. (23). 
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Fig. 4. European liver transplantation centers in July, 1984. barge dots have the 
same meaning as in Fig. 3. By permission of Starzl et al (23). 
Using conventional immunosuppression with azathioprine or cyclo-
phosphamide and prednisone to which ALG was usually added, the one-
year survival was 55 (or 32.4%) of 170 consecutive recipients treated be-
tween 1963 and the end of 1979 (Fig. 2). Twenty-four of the 55 one-year 
survivors died subsequently, so that of the original 170 recipients, 31 
(18.2%) are still alive with followups now of5 to 15 years. There have been 
only two deaths after 5 years. 
During the 5-year period since the combination therapy with cyclo-
sporine and steroids was instituted, the expectation of one-year survival 
of 199 consecutive patients treated up to November 1, 1984 rose to 70% 
(Fig. 2). 
In Figure 5, our experience in the cyclosporine era is broken down by 
calendar years beginning with 1980. In 1980, 14 new patients treated 
with cyclosporine-steroids were entered. In spite of two deaths on the 
operating table, 11 (78.6%) of these 14 patients survived for a year. Seven 
of the 14 still survive, 4 to 5 years later. In 1981, two-thirds of our patients 
lived for a year and 58% are still living (Fig. 5). 1982 was a special year in 
that for the first time multiple and interchangeable donor and recipient 
teams were assembled and trained in response to the need for large case 
volume. Sixty-two new recipients were enrolled in 1982 with primary 
grafts and, in addition, 18 retransplantations were performed for a grand 
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Fig. 5. One-year survival from year-to-year using cyclosporine and steroids begin-
ning in 1980. 1982 was the first year when multiple donor and recipient teams were 
trained and the first year ofa truly large case load. The statistics from 1984 are for 
the first 11 months. 
total that year of 80 transplantations. The one-year survival for new pa-
tients in 1982 fell to 50% as the multiple teams paid the price of working 
on a learning curve. The payoff came in 1983 when 76 new patients were 
entered, and in 1984 during which 121 new recipients were treated in the 
first 11 months at a pace which projected at about 140 for the full present 
year. The actuarial or actual survival at one year is better than 80% (Fig. 
5). In fact, almost 90% of the patients treated in 1984 are still living. 
Thus, liver transplantation has become safe to a degree not even easily 
dreamed of only 2 or 3 years ago. 
In assessing these results, an important potential artifact must be ex-
amined. Since the beginning of our program, more than two decades ago, 
pediatric recipients have survived at a higher rate than adults. In Figure 
6 is shown the disparity in results between those recipients who were 18 
years of age or younger versus those in the adult age group. The diver-
gence of results has become even more striking in the cyclosporine era 
(Fig. 6). Thus, in looking at the results from any time in the history of our 
program, stratification of the adult and pediatric cases is necessary. 
In the entire pre-cyclosporine era through 1979, about half of the re-
cipients were pediatric (Fig. 7). Since that time, the pediatrics component 
of the overall case material has ranged from 20% to just under 50% but 
never as high as in the pre-cyclosporine era. Thus, improved overall sur-
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Fig. 6. Life survival of all pediatric patients versus all adults in the pre-
cyclosporine era and after the introduction of cyclosporine-steroid therapy. 
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thereafter. Statistics for 1984 are for the first 11 months. 
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viva I after the introduction of cyclosporine has not reflected a major shift 
downward in the candidate's age spectrum in comparison to the pre-
cyclosporine era. However, some of the yearly survival variations since 
1980 probably have been influenced by the age factor, especially during 
1984 when almost half of the recipients were pediatric. 
PROSPECTS FOR FURTHER REDUCTIONS IN MORTALITY 
Now that the vast majority ofliver recipients can be brought through 
the operation and the postoperative period, the mortality which remains 
has been felt more keenly than ever. Further improvements in both graft 
and patient survival should be feasible almost immediately. 
Improvements in Immunosuppression 
Almost all liver transplant centers now are using the double-drug 
program of cyclosporine and steroids. At first, pharmacologic monitoring 
was not available on a practical basis but there has been increasing de-
pendence on serial measurements of cyclosporine blood levels. The objec-
tive usually is to reach whole blood concentrations of800 to 1000 ng/ml as 
measured with the radioimmunoassay technique just before the next 
dose. This is referred to as the trough. In addition, renal function is 
carefully monitored, and if abnormalities occur, a downward adjustment 
in the doses is promptly made since cyclosporine's principal side-effect is 
nephrotoxici ty. 
The most dangerous time during the recovery is during the first few 
days or weeks postoperatively. During this time, the intravenous cyclo-
sporine is given while the gastrointestinal tract goes through the ex-
pected postoperative ileus, and even after this, the intravenous route is 
continued until absorption of oral dose can be d~cumented by measuring 
the trough levels (Fig. 8). 
In patients with draining T-tubes, the absorption of the oral drug 
often has been noticed to increase abruptly with T-tube clamping. This is 
not surprising since cylosporine is fat soluble. The general objective is to 
protect the patient from underdosage by using the intravenous route 
while at the same time working to establish an exclusively enteral route 
(Fig. 8.). 
In the past, the only option that was available if rejection occurred in 
spite of the foregoing management, was further steroid therapy (Fig. 8). 
Conventional ALG was sometimes tried, but the results were 
unpredictable. Often, the only way to save patients undergoing severe re-
jection was to make a quick decision for retransplantation. 
Beginning in the autumn of1984, a new and powerful tool was added 
to the immunosuppressive armamentarium, namely monoclonal OKT-3 
antibody (Ortho Corporation, Raritan, New Jersey). This agent is a high-
ly standardized ALG made with the mouse hydridoma technique (24). 
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Fig. 8. The use of cyclosporine and steroids. Note that the cyclosporine initially is 
given intravenously and that the intravenous therapy is continued long after the 
drug is begun orally. The switch from double-route cyclosporine therapy to the oral 
route alone is carefully monitored with cyclosporine blood levels. Note the seeming 
increase in enteral absorption after clamping of the T -tube, the insistence upon 
maintaining high blood levels of cyclosporine in spite of obvious low-grade 
nephrotoxicity, and the intensification of steroid therapy with either a cycle or in-
termittent bolus administration with suspicion of rejection. Large arrows = 1 
gram Solu-Medrol. Slender arrows = 1 gram Solu-Cortef. By permission of Starzl 
et al. (23). 
Now, if a rejection occurs which is sluggishly responsive or nonresponsive 
to steroid therapy, daily intravenous monoclonal antibody is given. The 
ability ofthis agent to reverse rejection of renal or hepatic homografts has 
been little short of spectacular. A further advantage of monoclonal anti-
body therapy is that cyclosporine doses can be reduced during the period 
of the ALG therapy. Frequently, patients who develop early and 
uncontrollable rejection also have renal failure, for which the 
cyclosporine is deterimental. By using an agent which is effective at re-
versing rejection, the need for high-dose cyclosporine treatment is re-
duced or eliminated with consequent relief of the associated renal failure. 
During the period of monoclonal antibody therapy (usually 10 to 14 
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days), an effort is made to tune the ultimate doses of steroids and 
cyclosporine to those which will be compatible with effective mainte-
nance. When this has been done, there has been a very low incidence of 
recurrence of rejection after discontinuance of the monoclonal antibody 
therapy. 
Technical Improvements 
V eno-Venous Bypasses 
During the period of vena caval and portal occlusion that is necessary 
during the final stages of total hepatectomy and during the construction 
of the graft's vascular anastomoses, veno-venous bypasses are being used 
without heparinization for almost all adult liver recipients, and for an 
increasing number of pediatric recipients. 
The bypasses which were developed in the last half of 1982 (25) and 
given extensive clinical trials in 1983 (26,27), have made liver transplan-
tation a very reasonable operation, and one that can be taught to younger 
surgeons under acceptable conditions. The improved state in which liver 
recipients are returned to the intensive care unit for convalescence after 
the introduction ofveno-venous bypasses has been documented by Shaw 
et al (27). The reasons have been several. With veno-venous bypasses dur-
ing operation, the necessity for volume pre loading to keep the patient 
alive has been drastically reduced, renal function has been protected to an 
extent not previously possible, and the sequestration of fluids in the ob-
structed venous beds has been all but eliminated. It has now become quite 
common to have patients enter the operating room in a nearly moribund 
state and to have them return from the liver transplantation as if they 
had undergone a routine procedure. 
Retransplantation 
Whenever one of our patients is doing badly, we look first to the graft 
for an explanation. If there is inadequate or questionable liver function 
because of uncontrolled rejection or other causes, we consider early 
retransplantation. Before 1980, 21 retransplantations had been at-
tempted in the first 170 recipients under conventional immunosuppres-
sion. There were only three examples of subsequent survival for as long as 
6 months, and even these three patients died 12, 13 and 16 months after 
receipt of their second liver. Their extended survival was a nightmare of 
morbidity from excessive steroid requirements. 
With the advent of cyclosporine, it has become obvious that patients 
after retransplantation often have a trouble-free postoperative period 
(28) Now the survival after retransplantation is about 50%. Thus, re-
transplantation has become a major factor in our improved results 
(24,18). 
As it was appreciated that retransplantation could be life-saving, the 
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Fig. 9. Incidence of retransplantation in each year since 1980 . Note that about one 
in five transplantations have been for homograft replacement in the last 4 years. 
number of such attempts increased. Figure 9 shows the year-by-year total 
from 1980 until the present year. About one out of every 5 hepatic grafts 
currently being used is for retransplantation. 
Other Technical Refinements 
One ofthe greatest advantages of using veno-venous bypasses, is that 
much more attention during the period of venous occlusion can be paid to 
obtaining perfect hemostasis in the hepatic fossa. When veno-venous by-
passes were not used, the urgency with which the new liver had to be sewn 
in was comparable to that in cardiac surgery during operations under 
inflow occlusion. The first objective was to keep the physiologically unsta-
ble period as short as possible. The niceties of hemostasis often had to be 
given second priority. 
Under veno-venous bypasses, it is possible to clean up the entire he-
patic fossa after the diseased native liver has been removed. The principle 
which is observed is to try to eliminate entirely the raw areas created by 
the total hepatectomy. The triangular and coronary ligaments are sewn 
with continuous hemostatic sutures, and eventually the rows of sutures 
are connected together to completely eliminate the bare areas. 
The classical complications of reconstruction ofhilar structures (he-
patic artery, portal vein, and ducts) which occurred at a high incidence a 
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number of years ago have been greatly reduced. Difficulties with biliary 
tract construction including obstruction or leakage have become rare, as 
have thromboses of the portal venous and hepatic arterial anastomoses. 
THE INTENSIVE CARE PHYSICIAN AND ORGAN PROCUREMENT 
Fiction has it that neurosurgeons provide most of the cadaveric do-
nors for organ transplantation. Of course, the cooperation of the 
neurosurgeons is absolutely vital not only in donor procurement, but also 
in the application of brain death criteria. Increasingly, however, it has 
been the intensive care physician with a high degree of social and moral 
conscience who has set into motion the chain of events leading to organ 
donation. If a brain dead donor is identified and shown to be stable, evalu-
ation and organ removal can proceed in an orderly way. Multiple organ 
harvesting that allows the removal of kidneys, liver, heart and other or-
gans from the same donor has become extremely common. 
Under ideal circumstances, the organs to be removed are dissected 
free in the presence of good circulation. They can then be infused with cold 
solutions, the distribution of which can be controlled by cross-clamping 
the aorta at different levels (29). These preparations by experienced sur-
geons require about 2 hours and for those who are slow or inexperienced 
this time can be doubled or tripled. 
If necessary, multiple organ procurement can be accomplished in a 
few minutes (23). This is important for intensive care physicians to know, 
since the impression has been created, or it has been explicitly taught by 
transplant surgeons, that cardiovascular stability is a prerequisite. To do 
the rapid procurement, one of the common iliac arteries or the terminal 
aorta is dissected free, encircled, ligated and caImulated with a large bore 
catheter after total body heparinization. The aorta is encircled again just 
above the diaphragm and cross-clamped at the same time as infusion with 
a cold solution is begun through the distal aortic cannula (Fig. 10.). Eight 
or ten liters of one of the potassium-rich preservation fluids is allowed to 
run in as quickly as possible in adults. Smaller volumes are used in chil-
dren. The lower vena cava is cut or decompressed into a bag on the floor to 
prevent organ injury from venous distention. 
The liver becomes cold to palpation within 1 or 2 minutes and it 
quickly becomes bloodless at the same time as the intestines become 
blanched. In animals, it has been shown that the interior of the liver 
reaches a cryoprotective range below 32°C within 2 or 3 minutes. Blood in 
the portal vein becomes almost hemoglobin-free within 1 or 2 minutes. 
Thus, double-flow infusion of the preservation fluid is achieved in a re-
markably effective way by infusion into the arterial system (Fig. 10,). 
U sing this method, dissection of the hilar structures is done only 
after the liver is blanched and chilled, by which time the kidneys are simi-
larly protected. If the anatomy of the hepatic hilum is familiar to the oper-
preservation 
f/{.LIci 
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Fig. 10. Method of :apid liver cooling that can be done without any preliminary 
dissection except for insertion of a distal aortic cannula and cross-clamping of the 
aorta at the diaphragm. The infusion fluid quickly gets into the portal system via 
the splanchnic capillary bed, providing double inflow cooling. By permission of 
Starzl et al (23). 
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ator, the hilar dissection can be done with great speed in a bloodless field. 
Rapid nephrectomy can also be carried out. 
This simplified method of multiple organ removal has been used to 
retrieve livers and kidneys from unstable donors, from donors who had 
already undergone cardiac arrest, and from donors whose heart or heart 
and lungs had already been removed. In Sweden, a country which does 
not yet have brain death laws, the technique has been applied success-
fully for organ harvest in non-heart beating cadaveric donors. The hepat-
ic, cardiac and renal grafts have uniformly been of good quality. 
SUMMARY 
Orthotopic liver transplantation was first carried out in the laborato-
ry almost 27 years ago, and in the human operating theater 22 years ago. 
Although the procedure was first considered experimental, it has been 
shown during the last five years how liver replacement can be made an 
indispensable part of the therapeutic armamentarium in hepatology. The 
pace at which technical improvements have been made and at which new 
knowledge has accumulated has been exponential in these recent years. 
Much of the recent progress in liver transplantation has been made 
by effective collaborations with talented critical care teams. Important 
questions of de.tail or even concept remain which will be resolved by a new 
group oftalented young men and women working in anesthesia and sur-
gery and in the intensive care units around the world. 
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